EXPrESSIVE-18NCT07850609
A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Trial sites expanded: 0 → 7 locations
- Start date changed from estimate of Oct 29, 2026 to Oct 27, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants Who Experience an Adverse Event (AE)
Timeframe: Up to approximately 4 months
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 2 months
Secondary (6)
Maximum Plasma Concentration (Cmax) of Alimatravir in Plasma
Time to Maximum Plasma Concentration (Tmax) of Alimatravir in Plasma
Plasma Trough Concentration (Ctrough) of Alimatravir
Plasma Estradiol Concentration
Plasma Testosterone Concentration
Show 1 moreShow less
Plasma Dihydrotestosterone Concentration
Arms and interventions
AlimatravirExperimental
Alimatravir 11 mg will be taken once monthly (qm)
Drugs: Alimatravir
Sites
7 sites in 2 countries
United States 4, Canada 3